The regulation of muscle mass by endogenous glucocorticoids

Glucocorticoids are highly conserved fundamental regulators of energy homeostasis. In response to stress in the form of perceived danger or acute inflammation, glucocorticoids are released from the adrenal gland, rapidly mobilizing energy from carbohydrate, fat and protein stores. In the case of inflammation, mobilized protein is critical for the rapid synthesis of acute phase reactants and an efficient immune response to infection. While adaptive in response to infection, chronic mobilization can lead to a profound depletion of energy stores. Skeletal muscle represents the major body store of protein, and can become substantially atrophied under conditions of chronic inflammation. Glucocorticoids elicit the atrophy of muscle by increasing the rate of protein degradation by the ubiquitin-proteasome system and autophagy lysosome system. Protein synthesis is also suppressed at the level of translational initiation, preventing the production of new myofibrillar protein. Glucocorticoids also antagonize the action of anabolic regulators such as insulin further exacerbating the loss of protein and muscle mass. The loss of muscle mass in the context of chronic disease is a key feature of cachexia and contributes substantially to morbidity and mortality. A growing body of evidence demonstrates that glucocorticoid signaling is a common mediator of wasting, irrespective of the underlying initiator or disease state. This review will highlight fundamental mechanisms of glucocorticoid signaling and detail the mechanisms of glucocorticoid-induced muscle atrophy. Additionally, the evidence for glucocorticoids as a driver of muscle wasting in numerous disease states will be discussed. Given the burden of wasting diseases and the nodal nature of glucocorticoid signaling, effective anti-glucocorticoid therapy would be a valuable clinical tool. Therefore, the progress and potential pitfalls in the development of glucocorticoid antagonists for muscle wasting will be discussed.

[1]  J. Seckl,et al.  11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. , 2013, Physiological reviews.

[2]  J. Daly,et al.  Glucocorticoid blockade does not abrogate tumor-induced cachexia. , 1999, Nutrition and cancer.

[3]  D. Mann,et al.  TNF-acts via p 38 MAPK to stimulate expression of the ubiquitin ligase atrogin 1 / MAFbx in skeletal muscle , 2005 .

[4]  M. Exton Infection-Induced Anorexia: Active Host Defence Strategy , 1997, Appetite.

[5]  N. Offner,et al.  The initiation factor eIF 3f is a major target for Atrogin 1 / MAFbx function in skeletal muscle atrophy , 2013 .

[6]  D. Attaix,et al.  Myostatin Gene Deletion Prevents Glucocorticoid- Induced Muscle Atrophy , 2022 .

[7]  W. Mitch,et al.  Metabolic acidosis stimulates protein degradation in rat muscle by a glucocorticoid-dependent mechanism. , 1986, The Journal of clinical investigation.

[8]  Charles Keller,et al.  NF-κB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. , 2013, The Journal of clinical investigation.

[9]  P. Felig,et al.  Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in man. , 1973, The Journal of clinical investigation.

[10]  J. Wang,et al.  Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids. , 1996, The Journal of clinical investigation.

[11]  H. Cushing The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). 1932. , 1994, Obesity research.

[12]  Yanjun Dong,et al.  Myostatin Suppression of Akirin1 Mediates Glucocorticoid-Induced Satellite Cell Dysfunction , 2013, PloS one.

[13]  W. Alkema,et al.  Prednisolone-induced differential gene expression in mouse liver carrying wild type or a dimerization-defective glucocorticoid receptor , 2010, BMC Genomics.

[14]  D. Lacey,et al.  Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival , 2010, Cell.

[15]  T. Speed,et al.  Genome-wide analysis of glucocorticoid receptor-binding sites in myotubes identifies gene networks modulating insulin signaling , 2012, Proceedings of the National Academy of Sciences.

[16]  D J Glass,et al.  Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy , 2001, Science.

[17]  Se-Jin Lee,et al.  Regulation of myostatin activity and muscle growth , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Goldberg,et al.  Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  N. Agell,et al.  Muscle hypercatabolism during cancer cachexia is not reversed by the glucocorticoid receptor antagonist RU38486. , 1996, Cancer letters.

[20]  D. Marks,et al.  Pathophysiology and treatment of inflammatory anorexia in chronic disease , 2010, Journal of cachexia, sarcopenia and muscle.

[21]  D. Marks,et al.  Cancer‐ and endotoxin‐induced cachexia require intact glucocorticoid signaling in skeletal muscle , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  S. Anker,et al.  Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). , 2013, European heart journal.

[23]  S. Bhatnagar,et al.  The TWEAK–Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice , 2010, The Journal of cell biology.

[24]  B. Langley,et al.  Myostatin Inhibits Myoblast Differentiation by Down-regulating MyoD Expression* , 2002, The Journal of Biological Chemistry.

[25]  L. Ellisen,et al.  Dexamethasone Represses Signaling through the Mammalian Target of Rapamycin in Muscle Cells by Enhancing Expression of REDD1* , 2006, Journal of Biological Chemistry.

[26]  S. Bhasin,et al.  Characterization of 5'-regulatory region of human myostatin gene: regulation by dexamethasone in vitro. , 2001, American journal of physiology. Endocrinology and metabolism.

[27]  J. Spranger,et al.  Skeletal Muscle 11beta-HSD1 Controls Glucocorticoid-Induced Proteolysis and Expression of E3 Ubiquitin Ligases Atrogin-1 and MuRF-1 , 2011, PloS one.

[28]  R. Huupponen,et al.  Hepatic metabolism and distribution of mifepristone and its metabolites in rats. , 1994, Human reproduction.

[29]  A. Csibi,et al.  MAFbx/Atrogin-1 Controls the Activity of the Initiation Factor eIF3-f in Skeletal Muscle Atrophy by Targeting Multiple C-terminal Lysines* , 2009, Journal of Biological Chemistry.

[30]  P. Sawchenko,et al.  Cerebrovascular Cyclooxygenase-1 Expression, Regulation, and Role in Hypothalamic-Pituitary-Adrenal Axis Activation by Inflammatory Stimuli , 2009, The Journal of Neuroscience.

[31]  L. Tessitore,et al.  Pharmacological interference with tissue hypercatabolism in tumour-bearing rats. , 1994, The Biochemical journal.

[32]  C. Y. Wang,et al.  NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. , 2000, Science.

[33]  S. Bodine,et al.  The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. , 2008, American journal of physiology. Endocrinology and metabolism.

[34]  During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation , 2009, The Journal of cell biology.

[35]  J. Mages,et al.  Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock , 2006, The Journal of experimental medicine.

[36]  S. Bodine,et al.  Muscle sparing in muscle RING finger 1 null mice: response to synthetic glucocorticoids , 2011, The Journal of physiology.

[37]  Takashi Ushida,et al.  Translational Suppression of Atrophic Regulators by MicroRNA-23a Integrates Resistance to Skeletal Muscle Atrophy* , 2011, The Journal of Biological Chemistry.

[38]  A. Goldberg,et al.  Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  M. Kluger The evolution and adaptive value of fever. , 1978, American scientist.

[40]  W. Mitch,et al.  Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. , 2009, The Journal of clinical investigation.

[41]  J. Cidlowski,et al.  Glucocorticoid receptor signaling in health and disease. , 2013, Trends in pharmacological sciences.

[42]  Nicholas Ling,et al.  Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF‐κB‐independent, FoxO1‐dependent mechanism , 2006 .

[43]  V. Baracos,et al.  Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic–pituitary–adrenal axis , 2011, The Journal of experimental medicine.

[44]  Yi-Ping Li,et al.  Curcumin prevents lipopolysaccharide‐induced atrogin‐1/MAFbx upregulation and muscle mass loss , 2007, Journal of cellular biochemistry.

[45]  P. Sawchenko,et al.  Type 1 interleukin‐1 receptor in the rat brain: Distribution, regulation, and relationship to sites of IL‐1–induced cellular activation , 1995, The Journal of comparative neurology.

[46]  A. Goldberg,et al.  Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  K. Buller,et al.  Circumventricular Organs: Gateways to the Brain Role Of Circumventricular Organs In Pro‐Inflammatory Cytokine‐Induced Activation Of The Hypothalamic– Pituitary–Adrenal Axis , 2001, Clinical and experimental pharmacology & physiology.

[48]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[49]  W. V. Berghe,et al.  Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[50]  P. Wei,et al.  Transrepression of c-jun gene expression by the glucocorticoid receptor requires both AP-1 sites in the c-jun promoter. , 1998, Molecular endocrinology.

[51]  A. Goldberg,et al.  Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. , 1983, The New England journal of medicine.

[52]  W. Mitch,et al.  Mechanisms for defects in muscle protein metabolism in rats with chronic uremia. Influence of metabolic acidosis. , 1987, The Journal of clinical investigation.

[53]  N. Offner,et al.  The initiation factor eIF3‐f is a major target for Atrogin1/MAFbx function in skeletal muscle atrophy , 2008, The EMBO journal.

[54]  P. Sawchenko,et al.  Evidence for an Intramedullary Prostaglandin-Dependent Mechanism in the Activation of Stress-Related Neuroendocrine Circuitry by Intravenous Interleukin-1 , 1997, The Journal of Neuroscience.

[55]  Y. Itoyama,et al.  NO production results in suspension-induced muscle atrophy through dislocation of neuronal NOS. , 2007, The Journal of clinical investigation.

[56]  S. Melmed,et al.  Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion. , 1995, The Journal of clinical investigation.

[57]  H. Zhang,et al.  Endothelial-Specific Knockdown of Interleukin-1 (IL-1) Type 1 Receptor Differentially Alters CNS Responses to IL-1 Depending on Its Route of Administration , 2007, The Journal of Neuroscience.

[58]  K. Seibert,et al.  Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[59]  S. Powers,et al.  p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting. , 2010, American journal of physiology. Cell physiology.

[60]  W. Frontera,et al.  IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. , 2004, Cell.

[61]  C. Lang,et al.  Hormone, cytokine, and nutritional regulation of sepsis-induced increases in atrogin-1 and MuRF1 in skeletal muscle. , 2007, American journal of physiology. Endocrinology and metabolism.

[62]  L. Muglia,et al.  Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Lisa Martin,et al.  Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer , 2009, Clinical Cancer Research.

[64]  M. Almeida,et al.  Glucocorticoids and Tumor Necrosis Factor α Increase Oxidative Stress and Suppress Wnt Protein Signaling in Osteoblasts* , 2011, The Journal of Biological Chemistry.

[65]  Keiichi Fukuda,et al.  Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. , 2011, Cell metabolism.

[66]  S. W. Wendelaar Bonga,et al.  The stress response in fish. , 1997, Physiological reviews.

[67]  H. Besedovsky,et al.  Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. , 1987, Science.

[68]  M. Sandri Autophagy in health and disease. 3. Involvement of autophagy in muscle atrophy. , 2010, American journal of physiology. Cell physiology.

[69]  R. Renkawitz,et al.  The glucocorticoid receptor. , 1991, Biochimica et biophysica acta.

[70]  Michael Karin,et al.  p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling , 2009, Cell.

[71]  C. Libert,et al.  Glucocorticoid receptor dimerization induces MKP1 to protect against TNF-induced inflammation. , 2012, The Journal of clinical investigation.

[72]  A. Goldberg,et al.  Patterns of gene expression in atrophying skeletal muscles: response to food deprivation , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[73]  P. Herrlich,et al.  Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor , 2001, The EMBO journal.

[74]  Sandhya Sriram,et al.  Muscle-specific MicroRNA1 (miR1) Targets Heat Shock Protein 70 (HSP70) during Dexamethasone-mediated Atrophy* , 2013, The Journal of Biological Chemistry.

[75]  ChulHun Kang,et al.  Mechanism of glucocorticoid-induced oxidative stress in rat hippocampal slice cultures. , 2009, Canadian journal of physiology and pharmacology.

[76]  P. Hasselgren,et al.  PPARβ/δ Regulates Glucocorticoid- and Sepsis-Induced FOXO1 Activation and Muscle Wasting , 2013, PloS one.

[77]  Marco Sandri,et al.  Foxo Transcription Factors Induce the Atrophy-Related Ubiquitin Ligase Atrogin-1 and Cause Skeletal Muscle Atrophy , 2004, Cell.

[78]  P. Gluckman,et al.  The ubiquitin ligase Mul1 induces mitophagy in skeletal muscle in response to muscle-wasting stimuli. , 2012, Cell metabolism.

[79]  HORMONAL REGULATION , 1938, British medical journal.

[80]  J. Wrana,et al.  Myostatin Signals through a Transforming Growth Factor β-Like Signaling Pathway To Block Adipogenesis , 2003, Molecular and Cellular Biology.

[81]  N. Rosenthal,et al.  Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. , 2005, The Journal of clinical investigation.

[82]  D. Allen,et al.  Posttranscriptional mechanisms involving microRNA-27a and b contribute to fast-specific and glucocorticoid-mediated myostatin expression in skeletal muscle. , 2011, American journal of physiology. Cell physiology.

[83]  H. Cushing The Basophil Adenomas of the Pituitary Body and Their Clinical Manifestations (Pituitary Basophilism) , 1964 .

[84]  Shuhong Zhao,et al.  Identification of microRNAs involved in dexamethasone-induced muscle atrophy , 2013, Molecular and Cellular Biochemistry.

[85]  T. Claus,et al.  Hormonal regulation of hepatic gluconeogenesis and glycolysis. , 1988, Annual review of biochemistry.

[86]  A. Goldberg,et al.  Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting. , 1993, The American journal of physiology.

[87]  K. H. Richter,et al.  The DNA Binding-Independent Function of the Glucocorticoid Receptor Mediates Repression of Ap-1–Dependent Genes in Skin , 1999, The Journal of cell biology.

[88]  Qing Zhao,et al.  TRAF6 Inhibition Rescues Dexamethasone-Induced Muscle Atrophy , 2014, International journal of molecular sciences.

[89]  D. Laber,et al.  11 { beta }-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle , 2011 .

[90]  R. Sapolsky,et al.  Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. , 1987, Science.

[91]  K. Kalantar-Zadeh,et al.  Mid-arm muscle circumference and quality of life and survival in maintenance hemodialysis patients. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[92]  S. Bodine,et al.  Altered gene expression patterns in muscle ring finger 1 null mice during denervation- and dexamethasone-induced muscle atrophy. , 2013, Physiological genomics.

[93]  S. Rakhilin,et al.  The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. , 2007, Cell metabolism.

[94]  Nicolas Lützner,et al.  FOXO3 Is a Glucocorticoid Receptor Target and Regulates LKB1 and Its Own Expression Based on Cellular AMP Levels via a Positive Autoregulatory Loop , 2012, PloS one.

[95]  B. Hart Biological basis of the behavior of sick animals , 1988, Neuroscience & Biobehavioral Reviews.

[96]  K. Kaestner,et al.  DNA Binding of the Glucocorticoid Receptor Is Not Essential for Survival , 1998, Cell.

[97]  P. Hasselgren,et al.  Sepsis upregulates the gene expression of multiple ubiquitin ligases in skeletal muscle. , 2003, The international journal of biochemistry & cell biology.

[98]  Alexander Doyle,et al.  Toll‐like receptor 4 mediates lipopolysaccharide‐induced muscle catabolism via coordinate activation of ubiquitin‐proteasome and autophagy‐lysosome pathways , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[99]  Steven F. Maier,et al.  Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: evidence for vagal mediation of immune-brain communication , 1995, Neuroscience Letters.

[100]  K. D. Zylan,et al.  Article , 1996, Physiology & Behavior.

[101]  C. Dinarello,et al.  Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. , 1986, Science.

[102]  H. D. Hoberman Endocrine Regulation of Amino Acid and Protein Metabolism during Fasting * , 1950, The Yale journal of biology and medicine.

[103]  J. Fischer,et al.  Tumour necrosis factor (TNF) and interleukin-1 (IL-1) induce muscle proteolysis through different mechanisms , 1992, Mediators of inflammation.

[104]  A. Goldberg,et al.  FoxO3 controls autophagy in skeletal muscle in vivo. , 2007, Cell metabolism.

[105]  Jiandie D. Lin,et al.  PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription , 2006, Proceedings of the National Academy of Sciences.